NT-I7 ( DrugBank: NT-I7 )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 25 | Progressive multifocal leukoencephalopathy | 1 |
25. Progressive multifocal leukoencephalopathy
Clinical trials : 26 / Drugs : 35 - (DrugBank : 22) / Drug target genes : 8 - Drug target pathways : 37
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04781309 (ClinicalTrials.gov) | May 5, 2021 | 3/3/2021 | NT-I7, a Long-Acting Recombinant IL-7 Molecule, as an Immune Reconstitution Strategy for Lymphopenia in Patients With Progressive Multifocal Leukoencephalopathy | A Pilot Study of NT-I7, a Long-Acting Recombinant IL-7 Molecule, as an Immune Reconstitution Strategy for Lymphopenia in Patients With Progressive Multifocal Leukoencephalopathy | Progressive Multifocal Leukoencephalopathy | Drug: NT-I7 | National Institute of Neurological Disorders and Stroke (NINDS) | NULL | Recruiting | 18 Years | N/A | All | 12 | Early Phase 1 | United States |